Document is current
Any future updates will be listed below
-
Authors
Danenberg, Esther https://orcid.org/0000-0002-1799-4457
Bardwell, Helen
Zanotelli, Vito R. T.
Provenzano, Elena https://orcid.org/0000-0003-3345-3965
Chin, Suet-Feung https://orcid.org/0000-0001-5697-1082
Rueda, Oscar M. https://orcid.org/0000-0003-0008-4884
Green, Andrew https://orcid.org/0000-0002-0488-5913
Rakha, Emad
Aparicio, Samuel https://orcid.org/0000-0002-0487-9599
Ellis, Ian O. https://orcid.org/0000-0001-5292-8474
Bodenmiller, Bernd https://orcid.org/0000-0002-6325-7861
Caldas, Carlos https://orcid.org/0000-0003-3547-1489
Ali, H. Raza https://orcid.org/0000-0001-7587-0906
- License Information
-
More Information
Article History
Received: 23 September 2021
Accepted: 3 March 2022
First Online: 18 April 2022
Competing interests
: C.C. is a member of AstraZeneca’s iMED External Science Panel and Illumina’s Scientific Advisory Board and a recipient of research grants (administered by the University of Cambridge) from Genentech, Roche, AstraZeneca and Servier. B.B. holds a patent relevant to this work entitled ‘A method for determining the likelihood of a patient being responsive to cancer immunotherapy’ (publication number WO2020207771A1). E.P. has received honoraria from Roche and Novartis for speaking at meetings and Inflection Point Biomedical Advisors for participating in an advisory panel. The other authors declare no competing interests.
